Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 0.80 | 1.29 | 0.49 |
Stocks | 99.21 | 99.21 | 0.00 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 22.24 | 21.19 |
Price to Book | 4.56 | 4.17 |
Price to Sales | 2.62 | 2.49 |
Price to Cash Flow | 18.48 | 17.33 |
Dividend Yield | 1.67 | 1.32 |
5 Years Earnings Growth | 13.55 | 13.72 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 99.57 | 94.96 |
Basic Materials | 0.33 | 1.65 |
Consumer Defensive | 0.06 | 3.56 |
Financial Services | 0.04 | 9.42 |
Number of long holdings: 194
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 9.46 | 789.32 | +4.55% | |
UnitedHealth | US91324P1021 | 6.37 | 606.79 | +0.16% | |
Novo Nordisk B | DK0062498333 | 5.00 | 758.8 | +1.80% | |
J&J | US4781601046 | 4.68 | 154.52 | -0.01% | |
AbbVie | US00287Y1091 | 4.08 | 181.14 | +2.30% | |
Merck&Co | US58933Y1055 | 3.52 | 101.62 | +0.45% | |
Novartis | CH0012005267 | 2.90 | 91.93 | 0.00% | |
Roche Holding Participation | CH0012032048 | 2.86 | 251.40 | -0.83% | |
Thermo Fisher Scientific | US8835561023 | 2.77 | 512.98 | -0.24% | |
AstraZeneca | GB0009895292 | 2.77 | 10,492.0 | +0.17% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Legal General US Index Trust I Acc | 1.7B | 7.04 | 14.13 | 15.25 | ||
Legal General US Index Trust I Dist | 1.81B | 7.05 | 14.13 | 15.25 | ||
Legal General US Index Trust C Acc | 3.71B | 14.61 | 10.47 | 14.99 | ||
Legal General US Index Trust C Dist | 882.24M | 14.53 | 10.45 | 14.98 | ||
Legal General US Index Trust F Acc | 567.49K | 14.34 | 10.15 | 14.66 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review